"Turpentine VC" | Venture Capital and Investing · 20 August 2024 · 1 h 23 min
Listen at the source: Erik Torenberg ↗ · audio
This week on Turpentine VC, we’re releasing a conversation between Erik Torenberg, Laura Deming of The Longevity Fund and Will Eden of Sylvan Consulting (prior to that, with Thiel capital) focused on the past, present and future of biotech. Recorded in 2019, they discuss platform companies and the evolving biotech investment landscape, examining segments like therapeutics, cell and gene therapies. Will and Laura share insights on the historical waves of biotech, the FDA's role, and the intersections of biotech and tech investment strategies. They address challenges in evaluating biotech startups, the growth in longevity research since 2011, and the potential for extending life spans through various scientific advancements. 🔥 Apply to join over 400 founders and Execs in the Turpentine Network: https://hmplogxqz0y.typeform.com/to/JCkphVqj — RECOMMENDED PODCASTS: 🎙️ This Won't Last - Eavesdrop on Keith Rabois, Kevin Ryan, Logan Bartlett, and Zach Weinberg's monthly backchannel. They unpack their hottest takes on the future of tech, business, venture, investing, and politics. Apple Podcasts: https://podcasts.apple.com/us/podcast/id1765665937 Spotify: https://open.spotify.com/show/2HwSNeVLL1MXy0RjFPyOSz YouTube: https://www.youtube.com/@ThisWontLastpodcast — SPONSORS: 🛠️ Building an enterprise-ready SaaS app? WorkOS has got you covered with easy-to-integrate APIs for SAML, SCIM, and more.
As published with the episode at "Turpentine VC" | Venture Capital and Investing ↗
No summary of this episode yet.